Kwangdong Healthbio Co., Ltd. (XKON:086220)
1,468.00
-32.00 (-2.13%)
At close: Aug 1, 2025, 3:30 PM KST
Verve Therapeutics Revenue
In the year 2014, Kwangdong Healthbio had annual revenue of 38.10B KRW with 19.85% growth.
Revenue
38.10B
Revenue Growth
-2.50%
P/S Ratio
0.41
Revenue / Employee
470.33M
Employees
81
Market Cap
15.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2014 | 38.10B | 6.31B | 19.85% |
Dec 31, 2013 | 31.79B | -4.07B | -11.35% |
Dec 31, 2012 | 35.86B | 6.04B | 20.27% |
Dec 31, 2011 | 29.81B | -17.09B | -36.44% |
Dec 31, 2010 | 46.91B | 527.66M | 1.14% |
Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Electronics | 308.59T |
SK hynix | 77.21T |
LG Energy Solution | 25.76T |
Samsung Biologics | 4,898.69B |
Hanwha Aerospace | 15.28T |
Hyundai Motor Company | 178.98T |
HD Hyundai Heavy Industries | 15.32T |
Celltrion | 3,662.23B |